

DAFTAR PUSTAKA

1. Ghodke-Puranik Y, Thorn CF, Lamba JK, et al. Valproic Acid Pathway: Pharmacokinetics and Pharmacodynamics. *Pharmacogenet Genomics*. 2013; 23: 236-41.
2. Coppola G, Piccorossi, Operto FF and Verroti A. Anticonvulsant Drugs for generalized Tonic-Clonic Epilepsy. *Expert Opinion on Pharmacotherapy*. 2017.
3. Kelesidis T, Kelesidis L Chou S, Mantzoros CS. Narrative Review: The Role of Leptin in Human Physiology. Emerging Clinical Applications. *Ann Intern Med*. 2010; 152(2): 93-100.
4. Paz-Filho G, Mastronardi C, Franco CB, Wang KB, Wong ML, Licinio J. Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implications. *Arq Bras Endocrinol Metab*. 2012; 56(9): 597-607.
5. Mora-Muñoz L, Guerrero-Naranjo A, Rodríguez-Jimenez EA, Mastronardi CA, Velez-van-Meerbeke A. Leptin: role over central nervous system in epilepsy. *BMC Neurosci*. 2018; 19(51): 1-9.
6. Min-Dian Li. Leptin and Beyond: An odyssey to the central control of Body Weight. *Yale J Biol Med*. 2011. 84: 1-7.
7. Berenson GS, Wattigney WA and Tracy RE. Atherosclerosis of The Aorta and Coronary Arteries and Cardiovascular Risk Factors in Persons Aged 6 to 30 Years and Studied at Necropsy (The Bogalusa Heart Study). *Am J Cardiol*. 1992; 70: 851-8.
8. Facey A, Dilworth L, Irving R. A Review of the Leptin Hormone and the Association with Obesity and Diabetes Mellitus. *J Diabetes Metab*. 2017; 8(3): 1-3.
9. Annegers JF, Hauser WA and Shirts SB. Heart Disease Mortality and Morbidity in Patients with Epilepsy. *Epilepsia*. 1984; 25: 699-704.
10. Akgün A, Köken T, Kahraman A. Evaluation of adiponectin and leptin levels and oxidative stress in bipolar disorder patients with metabolic syndrome treated by valproic acid. *J Psychopharmacol*. 2017: 1-7.
11. Cansu A, Serdaroglu A, Çamurdan O, Hırfanoğlu T, Cinaz P. Serum Insulin, Cortisol, Leptin, Neuropeptide Y, Galanin and Ghrelin Levels in Epileptic Children Receiving Valproate. *Horm Res Paediatr*. 2011; 76: 65–71.
12. Genc BO, Dogan EA, Dogan U, Genc E. Anthropometric indexes, insulin resistance, and serum leptin and lipid levels in women with cryptogenic epilepsy receiving topiramate treatment. *J Clin Neurosci*. 2010; 17:1256-9.
13. Ghanizadeh A. Leptin as a new approach for treatment for autism and epilepsy, a hypothesis with clinical implications. *Brain & Development*. 2011; 33: 92–3.
14. Paz-Filho G, Wong ML. The procognitive effects of leptin in the brain and their clinical implications. 2010. *Int J Clin Pract*; 64(13): 1808–12.
15. Kim DW, Yoo MW, Park KS. Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients. *Epilepsy & Behavior*. 2012; 23: 497–9.

16. Lagace DC, Mcleod DS, Nachtiga MW. Valproic Acid Inhibits Leptin Secretion and Reduces Leptin Messenger Ribonucleic Acid Levels in Adipocytes. *Endocrinology*. 2014; 145(12): 5493–503.
17. Myers MG, Cowley MA, Munzberg H. Mechanisms of Leptin Action and Leptin Resistance. *Annu. Rev. Physiol.* 2008; 70: 537–56.
18. Palmio J, Vuolteenaho K, Lehtima K, Nieminen R, Peltola J, Moilanen E. CSF and plasma adipokines after tonic-clonic seizures. *Seizure*. 2016; 39: 10–2.
19. Wasim M. Role of Leptin in Obesity. *J Obes Weight Loss Ther.* 2015; 5:2.
20. Sidhua HS, Srinivas R, Sadhotra A. Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study. *Seizure* 2017; 48: 15–21.
21. Sonmez FM, Zaman D, Aksoy A, Deger O, Aliyazicioglu R, Karaguzel GL, Fazlioglu G. The effects of topiramate and valproate therapy on insulin, c-peptide, leptin, neuropeptide Y, adiponectin, visfatin, and resistin levels in children with epilepsy. *Seizure* 2017; 48: 1-6.
22. Lia XM, Yanb HJ, Guoa YS, Wang D. The role of leptin in central nervous system diseases. *NeuroReport*. 2016; 27: 350–5.
23. Yakubov B, Berall G, Hwang P. Seizures in patients with leptin receptor deficiency: Coincidence or close correlation?. *Clinical Neurophysiology* 2014; 215: e49–e52.
24. Li MD. Leptin and Beyond: An odyssey to the central control of Body Weight. *Yale J Biol Med.* 2011; 84: 1-7.
25. Adam JMF. Dislipidemia. In: Sudoyo AW, Setiyohadi B and Alwi I, (eds.). *Ilmu Penyakit Dalam*. 4 ed. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia, 2006, p. 1948-54.
26. Nikmah UL, Dany F. Leptin Level as Diabetes Marker in diabetic and impaired Glucose Tolerance Person. *Buletin Penelitian Kesehatan*. 2017. 45(3): 145-52.
27. Mohseni J, Zabidi-Hussin JAMH, Sasongko TH. Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy. *Genetics and Molecular Biology*. 2013. 36(3): 299-307
28. Buettner, C, Poci A, D. Muse E, M. Etgen, G. Myers M, Rossetti L, Critical role of STAT3 in leptin's metabolic actions. 2006. *Cell Metabolism* 4., 49–60,
29. Fiedor E, Zajda K, Gregoraszcuk E. Leptin Receptor Antagonists' Action on HDAC Expression Eliminating the Negative Effects of Leptin in Ovarian Cancer. *Cancer Genomics & Proteomics*. 15: 329-336 (2018)
30. Dhiraj G. Kabral. Hypothalamic leptin action is mediated by histone deacetylase 5. *Nature Communication*. 7:10782
31. Phiel C, Zhang F, Huang Y, Guenther M. Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and

- Teratogen. *J Biol Chem*. Vol. 276, No. 39, Issue of September 28, pp. 36734–36741
32. Canbay A, Bechmann L, Gerken G. Lipid Metabolism in The Liver. *Gastroenterol*. 2007; 45: 35-41.
 33. Paino F, La Noce M, Tirino V, Naddeo Q, Desiderio D, Pirozzi G et al. Histone Deacetylase Inhibition with Valproic Acid Downregulates Osteocalcin Gene Expression in Human Dental Pulp Stem Cells and Osteoblasts: Evidence for HDAC2 Involvement. *Stem cells*. 2014; 32: 279–89
 34. Morgan AE, Mooney KM, Wilkinson SJ, Pickles NA and Auley MTM. Cholesterol Metabolism: A Review of How Ageing Disrupts The Biological Mechanism Responsible for Its Regulation. *Ageing Research Reviews*. 2016; 03: 1-41.
 35. Dagogo-jack S. Physiological and Hormonal Factors that Influence Leptin Production. In: Dagogo-jack S, editor. *Leptin Regulation and Clinical Applications*. USA: Springer. 2015; pp. 45-65.
 36. Friedman JM. The Function of Leptin in Nutrition, Weight, and Physiology. *Nutrition Reviews*. 2002; 60(10): 1-14.
 37. Brzeska A, Widrowska J, Smolewska E. Leptin as an Important Hormone and Immunomodulator in Adult and Childhood Rheumatoid Arthritis. *Global Journal of Immunology and Allergic Diseases*, 2013; 1: 16-24.
 38. Belcastro V, D'Egidio C, Striano P and Verrotti A. Metabolic and Endocrine Effects of valproic Acid Chronic Treatment. *Epilepsy Research*. 2013; 8: 1-23.
 39. WHO. Epilepsy. <https://www.who.int/news-room/factsheets/detail/epilepsy>. Diakses tanggal 29 Februari 2020.
 40. CDC. Epilepsy: Data and Statistics. <https://www.cdc.gov/epilepsy/data/index.html>. Diakses tanggal 29 Februari 2020.
 41. Song P, Liu Y, Yu X, Wu J, N Poon A, Demaio A, Wang W, Rudan I, Yee Chan K. 2017. Prevalence of epilepsy in China between 1990 and 2015: A systematic review and meta-analysis. *JOGH*. Vol. 7 No. 2
 42. Trinkka E, Kwan P, In Lee B, Dash A. Epilepsy in Asia: Disease burden, management barriers, and challenges. 2019. *Epilepsia*.; 60(S1):7–21.
 43. Fitriana R. Kementrian Kesehatan Republik Indonesia. <http://yankes.kemkes.go.id/read-epilepsi-4812.html>. Diakses tanggal 29 Februari 2020.
 44. Gijo'n-Conde T, Graciani A, Guallar-Castillo P, Aguilera MT, Rodriguez-Artalejo F, and R. Banegas J. 2015. Leptin Reference Values and Cutoffs for Identifying Cardiometabolic Abnormalities in the Spanish Population. *Rev Esp Cardiol*. 68(8):672–679
 45. Olstad R, Florholmen J, Svartberg J, H. Rosenvinge J, Birketvedt GS. 2011. Leptin in the General Population, Differences in Sex Hormones, Blood Lipids, Gender and Life Style Characteristics. *The Open Behavioral Science Journal*. vol. 5: 8-15

46. Singh H, Sidhu R, Sadhotra SA. 2017. Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study. *Seizure* 48: 15-21
47. Uluda F, Fiener U, Zorlu Y, Köseolu M. 2011. Serum Leptin Levels in Epileptic Patients Treated with Topiramate and Valproic Acid. *Turk J Neurol.* 2011; 17(1): 17-31